Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Fig. 3

Survival outcomes associated with second-line sintilimab plus docetaxel therapy. Kaplan-Meier plots summarizing the progression-free survival (PFS) (A) and overall survival (OS) (B) of the 30 patients who received sintilimab plus docetaxel therapy. The dotted lines indicate the 95% confidence intervals (CI). Vertical dotted lines indicate the 18-month and 24-month OS. The risk table below indicates the number of patients analyzed per time point. Tick marks indicate the censored patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us